Lior Alkalay

Lior Alkalay

InvestorPlace Contributor

Lior is a consummate professional; a passionate analyst and economist with comprehensive experience within the financial services sector. With nearly 10 years of experience in trading and investment, Lior has provided his clients with crisp, clear and thorough analysis. Before becoming an independent analyst, he was employed for several years as the director of sell-side research at a leading international broker.

Lior specializes in mid- to long-range stock and ETF analyses using an out-of-the-box investment approach. That approach includes top-down analysis to identify the most attractive sectors, and then he balances it with cherry-picking to find the best opportunities.

Recent Articles

Walt Disney Co (DIS): Will ESPN Bring Disney Stock Down?

By Lior Alkalay, InvestorPlace Contributor

With no major release in Q2, investors are left to focus on the ESPN results. Therefore, ESPN needs to stabilize for Disney stock to benefit.

CVS Health Corp: Sanders Out, CVS Stock In

By Lior Alkalay, InvestorPlace Contributor

CVS stock's upside potential is ready to be unleashed as a Sanders loss is almost certain and Berniecare risk becomes remote.

3 High-Yield, High-Value Bond Plays

By Lior Alkalay, InvestorPlace Contributor

If you want to play high-yield bonds, you should limit your risk by owning risk-averse bond funds like ANGL, VWEHX and HYS.

The Coca-Cola Co Vs PepsiCo, Inc: Which Sparkles More? (KO, PEP)

By Lior Alkalay, InvestorPlace Contributor

KO and PEP are in the same sector but with different models -- and margins -- that make one clearly superior to the other.

JPMorgan Chase & Co.: JPM Earnings Are Good, But Not Good Enough

By Lior Alkalay, InvestorPlace Contributor

JPM earnings , while beating estimates still reflected an overall weakness in JPMorgan, with investment banking weighting on performance.

3 Big Pharma Stocks to Buy, 3 to Avoid

By Lior Alkalay, InvestorPlace Contributor

Big Pharma stocks are under pressure as regulation threatens to curb drug prices and tax driven mergers are intercepted by the treasury.

Pandora Media Inc: It’s Make-or-Break Time for P Stock

By Lior Alkalay, InvestorPlace Contributor

If Pandora (P) cuts back on the royalties it pays, the stock could rally. But if it fails, Pandora stock will plunge even lower.

American Airlines Group Inc: Why You Should Avoid AAL Stock

By Lior Alkalay, InvestorPlace Contributor

American Airlines has a poor earnings record, failing to cut costs in bad times and grow in the good time. Simply put, AAL stock is not worth the risk.

Why You WANT Alphabet Inc (GOOGL) to Get Smaller

By Lior Alkalay, InvestorPlace Contributor

GOOGL Stock needs to scale back unprofitable investments such as Boston Dynamics, if it hopes to maintain its bullish price momentum.

MetLife Inc Is a Cherry Everyone Is Missing (MET)

By Lior Alkalay, InvestorPlace Contributor

Metlife stock has a solid intrinsic value and yet is priced cheaply just because MET is in the insurance business. This distortion will not last long.

Load More